The partners said they have agreed to work together on projects in a range of diseases, as well as establish research alliances with groups in China and Africa.
BGI was fined after found in 2015 to be conducting a genetics study illegally, according to the Global Times.
At the ICG-13 conference, BGI previewed a high-throughput sequencer, MGISEQ-T7, that will be commercially available in 2019 and have a throughput of up to 20,000 genomes per year.
The companies will offer BGI's DNBseq next-generation sequencing technology along with Gencove's ImputeSeq low-pass sequencing analysis pipeline.
Researchers plan to sequence a hundred Pacific Northwest orcas to aid in their conservation, the Associated Press reports.
With NIPT samples from more than 141,000 women in China, investigators retraced population structure, historical migrations, genetic associations, and more.
The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
BGI will study pancreatic cancer with a group at Johns Hopkins and develop a diagnostic test for preterm birth detection with Mount Sinai Hospital researchers.
The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.
Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.
Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.
In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.